AYTU BIOPHARMA, INC. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AYTU BIOPHARMA, INC. on May 21, 2025. The report details the results of the Company's 2025 Annual Meeting of Stockholders held on the same date. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Capital Market under the symbol "AYTU".
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and shareholder voting outcomes.
Material Changes and Voting Results
At the 2025 Annual Meeting, 4,329,439 shares were present in person or by proxy, representing approximately 70% of the 6,169,953 shares outstanding on the record date. All four proposals presented to shareholders were approved:
- Proposal 1 (Election of Directors): All incumbent directors were elected by a majority vote. Directors elected include Joshua R. Disbrow, John A. Donofrio, Jr., Carl C. Dockery, Abhinav "Abi" Jain, and Vivian H. Liu.
- Proposal 2 (Equity Plan Amendment): Shareholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of shares reserved for issuance by 300,000. The total shares reserved under the plan are now 500,000, excluding unissued shares from prior plans or returned shares.
- Proposal 3 (Auditor Ratification): Shareholders ratified the appointment of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ended June 30, 2025.
- Proposal 4 (Executive Compensation): Shareholders approved the non-binding advisory vote on executive compensation.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. The document serves as a disclosure of the voting results and the effective date of the equity plan amendment.
Key Facts for Investor Verification
- Verify the total number of shares reserved under the amended 2023 Equity Incentive Plan (500,000 shares).
- Confirm the re-election of the specific directors listed in Proposal 1.
- Review the full text of the Plan Amendment filed as Exhibit 10.1 for detailed terms.
- Note that the filing does not include updated financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.